Biomea Fusion Inc
NASDAQ:BMEA
Biomea Fusion Inc
Other Equity
Biomea Fusion Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomea Fusion Inc
NASDAQ:BMEA
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Equity
-$1.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Equity
$22.6B
|
CAGR 3-Years
765%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
71%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Equity
$8.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Equity
$18.7B
|
CAGR 3-Years
2 647%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
152%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Equity
$77.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
21%
|
CAGR 10-Years
25%
|
|
Biomea Fusion Inc
Glance View
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.
